Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

With the Squeeze Clearly Over, It’s Time to Ditch Clover

By Thomas Niel, InvestorPlace Contributor
Once traders who got into this short-squeeze situation cash out, CLOV stock appears destined to head back to around $7 per share.

Carnival’s Tough Challenges, Uncertain Outlook Make CCL Stock a Sell

By Larry Ramer, InvestorPlace Contributor
Among the hurdles faced by Carnival are its huge debt load and regulatory uncertainty. CCL stock should be sold by investors.

Lordstown Motors May Only Be the First Domino to Fall in the EV Sector

By Chris Markoch, InvestorPlace Contributor
RIDE stock is dropping on news that its pre-orders weren't binding commitments. In the speculative EV sector, Lordstown Motors will need to work hard to build investor trust.

The Owners of Bionano Stock Will Be Hurt by Dilution

By Alex Sirois, InvestorPlace Contributor
BNGO stock looks decent until you dive deeper and understand what's really going on. The shares' outlook isn't good.

It’s Time to Back Away From DraftKings Stock

By Dana Blankenhorn, InvestorPlace Contributor
The problem is with DraftKings' technology partner, SBTech, which short-sellers at Hindenburg Research say still does business where gambling is illegal.

Exercise Extreme Caution With Clover Health Stock

By Faizan Farooque, InvestorPlace Contributor
CLOV stock, like AMC and GameStop, is trading at an unrealistic valuation, and it's important to be cautious if you've already invested.

Senseonics Has Too Much Hope for Success Priced in Already

By Larry Ramer, InvestorPlace Contributor
Reddit investors might be weakening, and Senseonics has to contend with a tough competitor, making SENS stock unattractive.

The Risk-Reward Ratio of Zomedica Stock Looks Unfavorable

By Larry Ramer, InvestorPlace Contributor
Zomedica may have to contend with very difficult competition, and there are indications that Truforma is not very popular so far. ZOM stock looks very risky.

Vaxart Is Still Not Worth Anywhere Near Its Present Price

By Mark R. Hake, CFA
Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise.

Is the Ride Over for Lordstown Motors?

By Dana Blankenhorn, InvestorPlace Contributor
General Motors and Ford have moved on with their own electric pickups, leaving Lordstown Motors and RIDE stock with dim prospects.

7 Meme Stocks to Avoid So You Don’t Get Caught Holding the Bag

By Faizan Farooque, InvestorPlace Contributor
Meme stocks continue to be a thing, despite confounding analysts who are questioning whether they can survive on Reddit steam alone.

GameStop Shares Just Don’t Deliver on Value

By Wayne Duggan, InvestorPlace Contributor
GME stock is one of the most popular stocks of 2021 among retail traders. Unfortunately, the stock's valuation is difficult to justify.

Overvalued Fisker Stock Is Headed To $7 Due To Capital Need

By Mark R. Hake, CFA
Fisker could need another capital raise so watch out. FSR stock could drop below $7 if spending continues at current rates.

Castor Maritime Stock Looks Even Worse Than Before After This Reverse Split

By Muslim Farooque, InvestorPlace Contributor
CTRM stock will continue to shed value as it continues to pursue its aggressive expansion strategy at the expense of its shareholder value

Canoo Needs Capital And Shareholders Could Be Left Holding The Bag

By Mark R. Hake, CFA
Canoo will need more money within a year, so beware of buying its stock. GOEV could take a big hit as cash on hand dwindles if capital raises come later rather than sooner.

Majorly Overvalued Microvision Stock Is Worse Than A Gamble

By Mark R. Hake, CFA
MicroVision is still up for sale but no one is going to buy MVIS stock at this high price. It will not be sold at a 60% higher price than its comps given that it has no comparable sales.

Koss Stock Will Keep Sliding on Flagging Sales Numbers

By David Moadel, InvestorPlace Contributor
KOSS stock is mostly known as a meme stock, and the company will have to improve its financials before traders can take it more seriously.

It’s Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

By Larry Ramer, InvestorPlace Contributor
After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.

Castor Maritime Is Risking Long-Term Disappointment with Short-Term Fix

By Dana Blankenhorn, InvestorPlace Contributor
Castor Maritime is trying to solve a short-term problem, the shortage of bulk shipping, with a long-term problem, debt on old boats. CTRM stock still has an undeserved Reddit following.
Load More Articles